Ignite Creation Date:
2024-05-06 @ 7:16 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05950945
Status:
RECRUITING
Last Update Posted:
2024-07-05
First Post:
2023-05-22
Brief Title:
Trastuzumab Deruxtecan T-DXd in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Sponsor:
Daiichi Sankyo
Organization:
Daiichi Sankyo
Organization Data
Organization:
Daiichi Sankyo
Class:
INDUSTRY
Study ID:
DS8201-0001-CIS-MA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Daiichi Sankyo
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |